CH BIOTECH SER (08037)'s Pengbo Hainan Boron Neutron Hospital has released its first batch of clinical data: the ORR for end-stage patients with head and neck cancer reaches 80%.

From July 30 to August 1, the 22nd Japan Society of Neutron Capture Therapy Academic Conference (JSNCT-22) was held at Kyoto University in Japan. CH BIOTECH SER (08037) subsidiary Pengbo (Hainan) Neutron Boron Hospital presented real-world clinical data in the form of an oral report on the follow-up results at three months (90 days) post-treatment for the first ten head and neck cancer patients who received Boron Neutron Capture Therapy (BNCT). The data revealed that among the first 10 assessable patients, the complete response rate (CR) was 40%, the partial response rate (PR) was 40%, and the overall objective response rate (ORR) reached as high as 80%. All enrolled patients were advanced head and neck cancer patients with unresectable or recurrent diseaseindicating they had undergone first-line and second-line chemotherapy, radiation therapy, or targeted therapy, all of which had failed, resulting in high tumor resistance and significant deterioration in physical condition. In this patient population, the ORR for traditional single-agent chemotherapy or targeted therapy is typically only around 10% to 20%, making the 80% ORR a "breakthrough" performance. Pengbo Hainan Neutron Boron Hospital is the first and currently the only medical institution in China approved to conduct clinical applications of BNCT. The hospital has introduced the NeuCure neutron equipment and Steboronine boron drug, which is currently the only officially approved BNCT drug-device combination available worldwide. This combination has accumulated over 2,000 clinical studies globally, and since its overseas market launch in 2020, it has treated over 1,000 patients. Since the hospital officially began accepting patients on March 19, 2026, the number of patients who have completed treatment and successfully been discharged is approaching 50. This includes patients from 19 provinces as well as international patients from Russia, with 78% being male and 76% over the age of 51, covering all age groups from 20 to over 70 years old, demonstrating broad clinical applicability. It is noteworthy that the data from Pengbo Hainan Hospital is consistent with previous overseas reports indicating an ORR of 72.09% for BNCT treatment in recurrent head and neck cancer patients at six months, with even better performance. Currently, the core indications approved by the hospital are for unresectable locally advanced or recurrent malignant tumors of the head and neck, covering more than ten subtypes including nasopharyngeal carcinoma, paranasal sinus carcinoma, laryngeal cancer, oral cancer, tongue cancer, gum cancer, and salivary gland cancer. In terms of patient services, the hospital has launched a medical expense installment service in collaboration with banks; jointly introduced a medical insurance product for Hainan Boron Neutron therapy with AXA insurance; partnered with CITIC PRU to launch the Good Boron Friend medical insurance, creating a "insurance + medical + reinsurance + global resources" collaborative innovation model; additionally, the hospital has teamed up with BGI Group to initiate a public welfare support program, offering 50 patient aid slots, with a maximum subsidy of 100,000 yuan for individual treatment. As clinical research on the indications for BNCT progresses steadily worldwide and relevant guidelines are formulated at the national level, this precision cancer-fighting technology, hailed as the "crown jewel of radiation therapy," is bringing new treatment hope to patients with refractory tumors in China and globally.